

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/HFB3BEC35C0EN.html>

Date: September 2018

Pages: 48

Price: US\$ 3,500.00 (Single User License)

ID: HFB3BEC35C0EN

Abstracts

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Pipeline Review, H2 2018

SUMMARY

According to the recently published report 'Human cytomegalovirus 65 kDa Phosphoprotein - Pipeline Review, H2 2018'; Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - 65-kDa cytosolic phosphoprotein (pp65) counteracts the host antiviral immune response when activated and phosphorylated and by preventing IRF3 from entering the nucleus. It participates in the transactivation of viral major immediate-early genes by the recruitment of host IFI16 to the promoter of these genes.

The report 'Human cytomegalovirus 65 kDa Phosphoprotein - Pipeline Review, H2 2018' outlays comprehensive information on the Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 1, 1 and 2 respectively.

Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Oncology and Immunology which include indications Cytomegalovirus (HHV-5) Infections, Brain Tumor, Glioblastoma Multiforme (GBM), Human Immunodeficiency Virus (HIV) Infections (AIDS), Kidney Transplant Rejection, Liver Transplant Rejection, Lymphoma, Medulloblastoma, Multiple Myeloma (Kahler Disease), Recurrent Glioblastoma Multiforme (GBM), Recurrent Malignant Glioma and Recurrent Medulloblastoma.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)

The report reviews Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics and enlists all their major and minor

projects

The report assesses Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Overview

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix

Phosphoprotein or Tegument Protein UL83 or UL83) - Therapeutics Assessment
Assessment by Route of Administration

Assessment by Molecule Type

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix

Phosphoprotein or Tegument Protein UL83 or UL83) - Companies Involved in
Therapeutics Development

Hookipa Biotech AG

Immunomic Therapeutics Inc

Vakzine Projekt Management GmbH

Vaximm AG

VBI Vaccines Inc

Vical Inc

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Drug Profiles

Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile
Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target PP65 for Glioblastoma Multiforme, Medulloblastoma and Recurrent Malignant Glioma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CyMVectin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HB-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Triplex - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBI-1901 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPM-2001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VXM-65 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix

Phosphoprotein or Tegument Protein UL83 or UL83) - Dormant Products

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix

Phosphoprotein or Tegument Protein UL83 or UL83) - Discontinued Products

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix

Phosphoprotein or Tegument Protein UL83 or UL83) - Product Development Milestones

Featured News & Press Releases

Apr 17, 2018: VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients

Jan 17, 2018: VBI Vaccines Announces Dosing of First GBM Patient in Phase 1/2a Clinical Study of VBI-1901

Nov 22, 2017: Dr. Duane Mitchell Reports Findings of Study Aimed at Aggressive Brain Cancer

Nov 10, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017

Oct 11, 2017: Immunomic Therapeutics Offers Travel Fund for Clinical Trial Patients

Aug 28, 2017: VBI Vaccines to Present New Preclinical Data for its GBM

Immunotherapy, VBI-1901, at The Immuno-Oncology Summit

Aug 15, 2017: VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme

May 04, 2017: Hookipa Biotech Presents Positive Data from Phase 1 First-In-Human Trial of Vaccine Against Cytomegalovirus

Apr 05, 2017: VBI Vaccines to Present Update on VBI-1901 at the World Vaccine Congress

Jan 09, 2017: Hookipa Biotech Announces Publication in Clinical and Vaccine Immunology Highlighting Vaxwave as an Effective Viral Vector for Vaccination against Congenital Cytomegalovirus Infections

Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting

Oct 28, 2016: Data from Phase 1 Trial of Triplex Vaccine for Control of Cytomegalovirus Published in Blood

Oct 11, 2016: VBI Vaccines Completes Pre-IND Meeting for its Glioblastoma Immunotherapy Candidate

Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe

Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Hookipa Biotech AG, H2 2018
Pipeline by Immunomic Therapeutics Inc, H2 2018
Pipeline by Vakzine Projekt Management GmbH, H2 2018
Pipeline by Vaximm AG, H2 2018
Pipeline by VBI Vaccines Inc, H2 2018
Pipeline by Vical Inc, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Hookipa Biotech AG

Immunomic Therapeutics Inc

Vakzine Projekt Management GmbH

Vaximm AG

VBI Vaccines Inc

Vical Inc

I would like to order

Product name: Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/HFB3BEC35C0EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HFB3BEC35C0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

